背景:缺铁(ID)的诊断和治疗指南因适应症而异。
目的:我们回顾了全球所有可用的ID管理指南。
方法:在PubMed,科克伦,和EMBASE以及主要的专业协会网站,仅限于2004年1月1日至2014年6月30日之间发布的文件。
结果:在确定的127个指南中,29人被选中涉及29个专业协会,来自美国(n=8),欧洲(n=6),英国(n=4),加拿大(n=3),国际组织(n=2),法国(n=2),波兰(n=1),澳大利亚(n=1),墨西哥(n=1),日本(n=1)。共有22和27个指南提供了关于ID的诊断和治疗的建议,分别。要定义ID,所有指南都推荐了血清铁蛋白的浓度.其中一半(22个中的10个)提出转铁蛋白饱和度(TSAT)作为替代或补充诊断测试。要治疗ID,大多数指南(27个中的18个)建议在可能的情况下优先采用口头途径,特别是在孕前或孕后的儿童和妇女中。根据27个指南中的13个,应静脉内补充铁。尤其是慢性肾脏病(CKD)(n=7)和化疗引起的贫血(n=5)患者。ID的治疗目标包括血红蛋白浓度增加至10-12g/dL或正常化(n=8)和血清铁蛋白>100μg/L(n=7)或200μg/L(n=4)。对于后者,在某些情况下,比如CKD,铁蛋白浓度不应超过500μg/L(n=5)或800μg/L(n=5)。只有9个指南推荐TSAT作为目标,提出从20%到50%的各种门槛。
结论:对于ID的诊断,在大多数情况下,应考虑血清铁蛋白浓度为100μg/L的截止值,而TSAT应考虑为20%,除了在特殊情况下,包括月经量大的年轻健康女性。静脉补铁的新适应症正在出现。
BACKGROUND: Guidelines on the diagnosis and treatment of iron deficiency (ID) vary widely across indications.
OBJECTIVE: We reviewed all available
guidelines on the management of ID worldwide.
METHODS: A literature search was conducted in PubMed, Cochrane, and EMBASE and in main professional association websites, limited to documents published between 1 January 2004 and 30 June 2014.
RESULTS: Of 127 guidelines identified, 29 were selected, involving 29 professional associations and issued from the United States (n = 8), Europe (n = 6), Britain (n = 4), Canada (n = 3), international organizations (n = 2), France (n = 2), Poland (n = 1), Australia (n = 1), Mexico (n = 1), and Japan (n = 1). A total of 22 and 27
guidelines provided recommendations on diagnosis and treatment of ID, respectively. To define ID, all
guidelines recommended a concentration for serum ferritin. One-half of them (10 of 22) proposed transferrin saturation (TSAT) as an alternative or complementary diagnostic test. To treat ID, most of the
guidelines (18 of 27) recommended preferentially the oral route if possible, particularly in children and in women in the pre- or postpregnancy period. Iron supplementation should be administered intravenously according to 13 of 27 guidelines, particularly in patients with chronic kidney disease (CKD) (n = 7) and chemotherapy-induced anemia (n = 5). Treatment targets for ID included an increase in hemoglobin concentrations to 10-12 g/dL or normalization (n = 8) and serum ferritin >100 μg/L (n = 7) or 200 μg/L (n = 4). For the latter, in some situations, such as CKD, ferritin concentrations should not exceed 500 μg/L (n = 5) or 800 μg/L (n = 5). Only 9 guidelines recommended TSAT as a target, proposing various thresholds ranging from 20% to 50%.
CONCLUSIONS: It appears that for the diagnosis of ID, a cutoff of 100 μg/L for serum ferritin concentration should be considered in most conditions and 20% for TSAT, except in particular situations, including young healthy women with heavy menstrual flow. New indications of intravenous iron supplementation are emerging.